Enjoy complimentary customisation on priority with our Enterprise License!
The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market size is estimated to grow by USD 5,427.51 million between 2022 and 202 accelerating at a CAGR of 8.14%.
The growth of the non-Hodgkin lymphoma treatment market depends on several factors, including the recent approvals and strong pipeline, the growing geriatric population, and special drug designations. Although the market may face challenges such as limited access to treatment, non-Hodgkin lymphoma therapeutics market trends such as growing awareness about cancer and research grants and funding will propel the non-Hodgkin lymphoma (NHL) therapeutics market growth.
This non-Hodgkin lymphoma (NHL) therapeutics market report extensively covers market segmentation by distribution channel (hospital pharmacy, retail pharmacy, online pharmacy, and others), therapy (immunotherapy, targeted therapy, and chemotherapy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The recent approvals and strong pipeline are key factors driving the growth of the global NHL therapeutics market. Although many approved therapies are available for various types of blood cancer, the market experiences a huge unmet need for their treatment. Currently, many chemotherapy drugs are dominating the treatment landscape for several types of cancer. However, in the market, targeted and immunotherapies have a higher share compared with chemotherapies.
This can be attributed to limitations such as the long-lasting adverse effects of chemotherapies, which reduce patient adherence to the treatment. Moreover, targeted therapies and immunotherapies have emerged as a prevailing class of therapeutics, acting through the regulation of specific proteins and protein targets. The growing R&D in this space and ongoing clinical trials of late-stage molecules further support the growth prospects of the global non-Hodgkin lymphoma treatment market.
Growing awareness about cancer is the primary trend in the global NHL therapeutics market growth. The rise in awareness about cancer is one of the major trends driving the growth of the market. Various international and national-level campaigns are conducted to increase awareness about cancer and help early detection of the disease. For instance, organizations such as the American Social Health Association (ASHA) and the National Cervical Cancer Coalition (NCCC) implement initiatives to create awareness about the prevention and control of cervical cancer. Similarly, the CDC provides guidelines and conducts awareness programs to screen and vaccinate underserved individuals with cervical cancer.
Furthermore, Cancer Breakthroughs 2020, previously known as Cancer Moonshot 2020, is an initiative taken by the US government in 2016 for the development of research on vaccine-based immunotherapies to fight cancer. The aim of this project is to make therapies available to more patients while detecting the disease at an early stage. By inviting the pharmaceutical players to join the initiative, the Cancer Breakthroughs 2020 program plans on making the targeted therapies one of the major areas of focus of this project. Collectively, these initiatives are expected to increase awareness about cancer and the available treatments, including various targeted and immunotherapies treating non-hodgkin lymphoma during the forecast period.
Limited access to treatment is a major challenge to the growth of the global NHL therapeutics market. One of the major challenges faced by the market is limited access to treatment for most patients across the world. Most countries in North America and Europe have almost all the approved drugs for the treatment of non-hodgkin lymphoma. However, therapeutic options for the treatment of diseases are limited in developing and underdeveloped economies. Despite the high prevalence of various blood cancers, including non-hodgkin lymphoma, in these countries, the inadequate availability of treatment options makes it difficult for patients to undergo treatment on time. The high cost of therapeutics also makes treatment unaffordable to a significant share of the patient population in these countries, especially due to the unavailability of patient assistance programs, poor understanding of health insurance, and the lack of advanced healthcare infrastructure.
Moreover, the lack of advanced healthcare infrastructure and limited awareness about the disease are delaying treatment, which, in turn, is making treatment with a limited number of chemotherapies ineffective. A major share of the patients in India is from backward regions, which have limited access to the treatment of cancer indications. Various countries in Asia, South America, and Africa also face similar challenges. These factors are expected to hinder the growth of the non-Hodgkin lymphoma treatment market significantly during the forecast period.
The non-Hodgkin lymphoma treatment market research report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Non-Hodgkin Lymphoma Therapeutics Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the non-Hodgkin lymphoma treatment market.
AstraZeneca - The company offers non-Hodgkin lymphoma therapeutics such as T-cell engagers which are bispecific molecules that are engineered to redirect the immune systems to recognize and kill cancer cells. Also, the company engages in the discovery, development, manufacturing, marketing, and sale of pharmaceutical products.
The non-hodgkin lymphoma therapeutics market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The non-Hodgkin lymphoma treatment market share growth by the hospital pharmacy segment will be significant during the forecast period. The hospital pharmacy is the department of the hospital that deals with the procurement, storage, compounding, dispensing, manufacturing, testing, packaging, and distribution of drugs. Drug distribution systems in hospitals are classified into in-patient and out-patient. The hospital pharmacist is competent in drug procurement, handling, pricing, and dispensing. Moreover, hospital pharmacies accounted for the largest share of the global non-Hodgkin lymphoma therapeutics (NHL) market in 2022, which will continue to remain the largest segment during the forecast period.
Get a glance at the market contribution of various segments Request a PDF Sample
The hospital pharmacy segment was valued at USD 3,599.74 million in 2017 and continue to grow by 2021. In hospitals, pharmacists serve as a liaison between patients and doctors and offer drug information to the public and all other healthcare professionals. They also help patients to understand their medications and how to take them, and assist in specialized medical care, such as non-Hodgkin lymphoma. However, the drugs used in the treatment of non-Hodgkin lymphoma require skilled hospital pharmacists to provide a proper description of the non-Hodgkin lymphoma treatment drugs. Therefore, hospital pharmacy is expected to be the primary distribution channel for non-Hodgkin lymphoma treatment drugs, which will contribute to the growth of the hospital pharmacy segment of the global non-Hodgkin lymphoma (NHL) therapeutics market during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 41% to the growth of the global non-Hodgkin lymphoma treatment market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the non-Hodgkin lymphoma (NHL) therapeutics market during the forecast period. The growth of the market in this region is primarily driven by the sales of approved therapeutics for the treatment of various subtypes of non-Hodgkin lymphoma and the increasing prevalence of various hematologic cancer types, including non-Hodgkin lymphoma. Moreover, non-Hodgkin lymphoma is the 8th most prevalent cancer type in the US, which is the major market shareholder in North America. According to the American Cancer Society's estimates for 2022, non-Hodgkin lymphoma is one of the most common cancers in the US, accounting for about 4% of all cancers. Such a high prevalence of the disease demands advanced and specialized treatment options. Targeted therapies, such as VELCADE and CALQUENCE, have the potential to meet this requirement. Hence, the high prevalence of non-Hodgkin lymphoma is expected to drive the growth of the market in North America during the forecast period.
The outbreak of COVID-19 adversely affected all countries in North America, especially the US, in 2020. However, the routine chemotherapy or in-patient department treatments at hospitals for various cancers, including non-Hodgkin lymphoma, were not affected to a great extent, considering the urgency of the treatment, which, in turn, led to regular demand for non-Hodgkin lymphoma therapeutics. Thus, the non-Hodgkin lymphoma therapeutics market in North America witnessed a mixed impact in 2020 and Q1 2021. Moreover, like many other pharmaceutical products, non-Hodgkin lymphoma therapeutics were made available to the related stakeholders. Hence, the regional non-Hodgkin lymphoma treatment market will register growth during the forecast period.
The non-hodgkin lymphoma therapeutics market research report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Non-Hodgkin Lymphoma Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
174 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.14% |
Market growth 2023-2027 |
USD 5,427.51 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
7.6 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF!
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.